Atopic Dermatitis

The consensus summarizes contemporary real-world data showing that nearly 1 in 5 adolescents and adults with atopic dermatitis receive systemic corticosteroids.

REZOLVE-AD shows rezpegaldesleukin delivers durable atopic dermatitis control with monthly or quarterly dosing, supporting Nektar’s phase 3 plans.

A new molecular test offers clinicians a way to personalize treatment for moderate to severe atopic dermatitis and reduce therapeutic cycling, helping to achieve faster control and a better experience for patients.

Bispecific and trispecific biologics are being developed to achieve deeper clearance and more meaningful symptom relief.

At South Beach Symposium 2026, Mona Shahriari explores OX40/OX40L therapies for atopic dermatitis.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe atopic dermatitis (AD).

Atopia Therapeutics advances ATP-R13 as a promising oral therapy for atopic dermatitis (AD), showing significant efficacy and enhanced patent protection.

An educational smartphone app significantly reduced atopic dermatitis relapse in children, enhancing caregiver engagement and timely intervention.

Pediatric atopic dermatitis often leads to allergic comorbidities, increasing treatment needs and health care costs, according to a new Japanese study.

Phase 1 cohort 4 data show soquelitinib demonstrated sustained clinical activity through 8 weeks, including in patients with prior systemic therapy exposure.

A Winter Clinical Hawaii poster determined that roflumilast cream 0.05% is well tolerated and effective for diverse patient populations with atopic dermatitis

Connect Biopharma reveals innovative data on rademikibart's mechanism of action, highlighting its potential impact on atopic dermatitis and future clinical priorities.

Dupilumab demonstrates significant efficacy and safety in treating severe atopic dermatitis in children aged 6 months to 5 years, improving quality of life.

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate to severe atopic dermatitis.

Apogee Therapeutics reveals promising phase 1b trial results for zumilokibart, highlighting its potential as a durable treatment for atopic dermatitis.

Expert consensus clarifies systemic corticosteroid use in atopic dermatitis, emphasizing risks and advocating for advanced therapies for better patient outcomes.

Discover the 2025 advancements in AD treatment, including new therapies, pediatric approvals, and insights into effective management strategies.

Brad Glick, DO, MPH, and attendees discuss innovative treatments for atopic dermatitis, emphasizing the importance of patient comfort and modern nonsteroidal options.

At a recent Case-Based Roundtable® event, Aaron Farberg, MD, moderated a discussion of challenging atopic dermatitis cases spanning adult, adolescent, and pediatric patients.